Leiden, February 18th , 2014 Dear Patient Group Representative, We hope this note finds you well. When we last communicated, we announced that Prosensa had regained all rights to drisapersen […]
Dr. Giles Campion, Prosensa’s Chief Medical Officer (https://www.prosensa.eu/) presented an overview of the latest drisapersen results in this morning’s patient webinar. An analysis of the Phase III data suggests that […]
Dear all, As announced last week, Prosensa will organize a patient focused webinar on Tuesday 21st of January at 8 AM ET / 14hrs CET. Practical details required to dial […]
Leiden,The Netherlands,Jan. 16, 2014(GLOBE NEWSWIRE) –Prosensa Holding N.V.(NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 15, 2014– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 120 from Study 202, a Phase IIb open-label extension study of […]
Dear Patient Group Representative, We are writing as we would like to share with you that as of January 12, 2014, Prosensa has regained the rights to drisapersen from GSK […]
LEIDEN, Netherlands and LONDON, Jan. 13, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to […]
Help CureDuchenne Now! With only 5 days left in the year, CureDuchenne is doing all it can to raise the dollars needed to fund promising and innovative research to find […]
My son, Justin Paul Monastesse, was a gift and he lived with Duchenne for more than 25 years. Justin always had a great time even though it took 2 1/2 […]
